ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING
Thomas De Somer 1
Nele Deprez 1
Didier Baert 1
Mieke Deceuninck 2
Inge Huys 2
Veerle Mattens 3
An Sterckx 3
Stijn Vanden Branden 3
Erik Vanderstraeten 3
Jo Vandervoort 3
Nina Van Heddegem 3
Pieter Dewint 3
1 AZ Maria Middelares, Gent, Belgium
2 Sint Vincentius Ziekenhuis, Deinze, Belgium
3 OLV Ziekenhuis, Aalst, Belgium
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]